Vigil Neuroscience, Inc. Expected to Post Q1 2024 Earnings of ($0.57) Per Share (NASDAQ:VIGL)

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Analysts at Wedbush reduced their Q1 2024 earnings per share estimates for shares of Vigil Neuroscience in a report released on Tuesday, March 26th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.57) per share for the quarter, down from their previous estimate of ($0.48). The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.56) per share. Wedbush also issued estimates for Vigil Neuroscience’s Q2 2024 earnings at ($0.61) EPS and FY2024 earnings at ($2.33) EPS.

Several other research analysts have also recently issued reports on the company. Morgan Stanley cut Vigil Neuroscience from an “equal weight” rating to an “underweight” rating and decreased their price target for the stock from $13.00 to $4.00 in a research note on Tuesday, December 19th. HC Wainwright reissued a “buy” rating and issued a $24.00 price objective on shares of Vigil Neuroscience in a research note on Wednesday. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat, Vigil Neuroscience has an average rating of “Moderate Buy” and an average price target of $17.40.

Vigil Neuroscience Stock Performance

Shares of VIGL opened at $3.20 on Thursday. The stock has a fifty day moving average price of $3.06 and a 200 day moving average price of $4.32. Vigil Neuroscience has a 12 month low of $2.53 and a 12 month high of $11.11.

Institutional Investors Weigh In On Vigil Neuroscience

Hedge funds and other institutional investors have recently made changes to their positions in the company. Strs Ohio acquired a new position in Vigil Neuroscience in the fourth quarter valued at about $27,000. Royal Bank of Canada bought a new stake in shares of Vigil Neuroscience in the second quarter valued at about $33,000. California State Teachers Retirement System bought a new stake in Vigil Neuroscience during the second quarter worth about $50,000. Wells Fargo & Company MN raised its holdings in Vigil Neuroscience by 6,988.4% during the second quarter. Wells Fargo & Company MN now owns 6,096 shares of the company’s stock worth $57,000 after acquiring an additional 6,010 shares in the last quarter. Finally, MetLife Investment Management LLC bought a new stake in Vigil Neuroscience during the second quarter worth about $86,000. 83.64% of the stock is owned by institutional investors and hedge funds.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.